| genetic
disease, genetic engineering, custom chip design, genotyping
services, human high-throughput genotyping, microarray design,
genome, Apex, development, arrayed primer extension, SNP,
genomics, genetic testing services, SNP tests, DNA chip, arrayed primer
extension, microarray scanner, p53, drug development,
diagnostics, personalized treatment,
human medicine, SNP, biotechnology, technology transfer, gene, DNA test |
NEWS
of 2005
12.2005
Asper Biotech announces the release of its next DNA test
The HEREDITARY HEARING LOSS test (HHL DNA test). The
new test is a single assay, which enables comprehensive mutation detection
in a number of genes linked to HHL. The test covers 201 mutations in
multiple genes that underlie both nonsyndromic (Connexin 26, Connexin 30,
Connexin 31, Connexin 43, SLC26A4, SLC26A5, 12SrRNA, and tRNA Ser) and
certain syndromic (Cx26 and SLC26A4) causes of hearing loss. Asper's
hereditary hearing loss test has been extensively validated by
pre-screened patient DNA samples in a well-designed blind study. As our
previous published studies have shown, our tests are able to detect more
than 98% of the existing genetic variations, so it's well suited for
screening of known mutations related to hereditary hearing loss. The
development and validation of the HHL test has been a joint work between
Asper Biotech and Stanford University. For further information please look
http://www.asperbio.com/HHL.htm
or contact info@asperbio.com.
10.2005
Thalassemia assay updated, and the number of mutations screened for was
increased to 46
One of
the most validated test at Asper Biotech, the Thalassemia assay has been
updated by adding 9 new mutations to the test. The current test version
covers 40 mutations from beta-globin and six mutations from delta-globin
genes. This update was the first one from the major upgrade program, which
will be followed by additional updates to present mutations from different
globin genes. The recent update was conducted in collaboration with The
Cyprus Institute of Neurology and Genetics.
For further questions please contact Asper Biotech info@asperbio.com
09.2005 New publication has
been
published:
Zernant J, Kulm M, Dharmaraj S, den Hollander AI,
Perrault I, Preising MN, Lorenz B, Kaplan J, Cremers FP,
Maumenee I, Koenekoop RK, Allikmets R., Genotyping microarray
(disease chip) for leber congenital amaurosis: detection of
modifier alleles.
Invest
Ophthalmol Vis Sci. 2005 Sep;46(9):3052-9.
08.2005 New publication co-authored by Asper Biotech's
Scientists has been published:
Schrijver I, Oitmaa E, Metspalu A, Gardner P.
Genotyping Microarray for the Detection of More Than 200 CFTR
Mutations in Ethnically Diverse Populations. J
Mol Diagn. 2005 Aug;7(3):375-87
07.2005 New publication co-authored by Asper Biotech's
Scientists has been published:
Le Calvez F, Ahman A, Tonisson N, Lambert J,
Temam S, Brennan P, Zaridze DG, Metspalu A, Hainaut P.
Arrayed Primer Extension Resequencing of Mutations in the TP53
Tumor Suppressor Gene: Comparison with Denaturing HPLC and
Direct Sequencing.
Clin Chem. 2005
Jul;51(7):1284-7.
04.2005
Asper
Biotech's branch Asper Ophthalmics invites all interested to
its booth (#219) at the ARVO 2005 in Fort Lauderdale,
Florida, USA, on May 1-4.
Asper
will be represented at meeting of the Association for Research
in Vision and Ophthalmology (ARVO) 2005. The meeting will be
held in Fort
Lauderdale, Florida, USA on 1- 4 of May.
Asper welcomes all existing partners and everyone
interested in collaborating with Asper to attend the
conference and meet in its booth #219.
02.2005
Asper
plans launching five new tests in Q1 and Q2 2005
Asper
continues to establish and validate genetic tests targeting different
research and clinical areas. First version of Central nervous system (CNS)
chip is currently under development. CNS test will become available during
Q1 and it would be established as an open assay, whereby researchers are
free to customize the chip by including additional SNPs to already
existing set of markers. In couple of months Asper will launch a similar
test for screening a variety of SNPs from ABC Transporter genes. Later
this year several other tests will follow. For further questions please
contact info@asperbio.com
01.2005
Asper
launches new website
As
Asper is focusing its efforts on genetic testing, a new updated
website was launched. The website should provide initial information about
the tests as well as describe how to prepare and ship the samples for high
quality analysis. In addition for keeping our current customers and
partners updated about the latest news Asper plans to launch a
concentrated newsletter in Q1. For further questions please contact info@asperbio.com
|
|
|
